Large Trial Will Test Immune Modulators for Covid-19
Photo: Chia-Chi Charlie Chang
Photo: Chia-Chi Charlie Chang
On Oct. 15, NIH held a media telebriefing to announce the launch of an adaptive phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with Covid-19.
The trial, part of the Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, aims to determine if modulating that immune response can reduce the need for ventilators and shorten hospital stays.
Speakers included NCATS director Dr. Christopher Austin and NIH director Dr. Francis Collins, as well as Operation Warp Speed therapeutics lead Dr. Janet Woodcock, Johnson & Johnson chief scientific officer Dr. Paul Stoffels and Bristol Myers Squibb chief medical officer Dr. Samit Hirawat.